Vascular Solutions (VASC) Tops Q3 EPS by 1c; Issues Solid Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Needham & Company Reiterates Buy on Vascular Solutions (VASC) Following 3Q Report
October 25, 2016 8:32 AM EDTNeedham & Company reiterated a Buy rating and $58.00 price target on Vascular Solutions (NASDAQ: VASC) following the company's 3Q earnings report. Revenue was reported in-line with consensus at $41.8M. Adjusted EPS was $0.31 vs. consensus of $0.30. The EPS upside was driven by a lower than expected... More
